Arformoterol
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
- Arformoterol
- Pharmacist Assessment Report
- Arformoterol: Long-acting beta-2 agonist bronchodilator → hyperlucent lung
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Arformoterol: Long-acting beta-2 agonist bronchodilator → hyperlucent lung
One-Sentence Summary
Arformoterol is an inhaled long-acting beta-2 adrenergic agonist bronchodilator. The TxGNN model predicts it may be useful for hyperlucent lung, with a score of 0.9975. There are currently no clinical trials and no publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | hyperlucent lung |
| TxGNN Prediction Score | 0.9975 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, arformoterol belongs to the long-acting beta-2 agonist class, which relaxes airway smooth muscle and widens the airways.
Hyperlucent lung is a radiologic finding rather than a distinct disease. It can reflect underlying emphysema or air trapping, so any benefit would depend on the underlying cause. A bronchodilator could plausibly ease symptoms where airflow obstruction is present, but this link is indirect. No clinical evidence supports the prediction, and the high score should be treated as a model output only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 121883 | Labaneb Respules (2ml Each) | Packet of 5 respules | Not recorded |
Safety Considerations
- Drug Interactions: 145 interactions were found in the interaction screening. Examples are listed below.
- Moderate: isometheptene, famotidine, epinephrine, cisapride, clarithromycin, diethylpropion, dolasetron, ephedrine, fenfluramine, granisetron, levofloxacin, inhaled rapid-acting human insulin
- Minor: hydrocortisone, beclomethasone dipropionate, betamethasone, budesonide, dexamethasone
Package insert warnings and contraindications were not available in the compiled data. Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or publications (Evidence Level L5). The target is a radiologic finding rather than a defined disease, and the mechanistic link is weak.
To proceed, the following is needed:
- A clearly defined clinical target, such as the specific underlying disease behind the hyperlucent lung finding
- Supporting clinical or observational studies in that population
- Mechanism of action data
- Package insert warnings and contraindications from the India label
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.